Dynamics of the Immune Repertoire in Recurrent, Locally Advanced, and Stage IV NSCLC Treated With First-Line Chemotherapy
We investigated longitudinal immune repertoire remodeling in patients with recurrent, unresectable locally advanced, or metastatic NSCLC without targetable driver mutations treated with first-line chemotherapy.